Cargando…

IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action

Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecour, Sandrine, Andreadou, Ioanna, Bøtker, Hans Erik, Davidson, Sean M., Heusch, Gerd, Ruiz-Meana, Marisol, Schulz, Rainer, Zuurbier, Coert J., Ferdinandy, Péter, Hausenloy, Derek J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437922/
https://www.ncbi.nlm.nih.gov/pubmed/34515837
http://dx.doi.org/10.1007/s00395-021-00893-5
_version_ 1783752258288091136
author Lecour, Sandrine
Andreadou, Ioanna
Bøtker, Hans Erik
Davidson, Sean M.
Heusch, Gerd
Ruiz-Meana, Marisol
Schulz, Rainer
Zuurbier, Coert J.
Ferdinandy, Péter
Hausenloy, Derek J.
author_facet Lecour, Sandrine
Andreadou, Ioanna
Bøtker, Hans Erik
Davidson, Sean M.
Heusch, Gerd
Ruiz-Meana, Marisol
Schulz, Rainer
Zuurbier, Coert J.
Ferdinandy, Péter
Hausenloy, Derek J.
author_sort Lecour, Sandrine
collection PubMed
description Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit.
format Online
Article
Text
id pubmed-8437922
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84379222021-09-29 IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action Lecour, Sandrine Andreadou, Ioanna Bøtker, Hans Erik Davidson, Sean M. Heusch, Gerd Ruiz-Meana, Marisol Schulz, Rainer Zuurbier, Coert J. Ferdinandy, Péter Hausenloy, Derek J. Basic Res Cardiol Practical Guideline Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit. Springer Berlin Heidelberg 2021-09-13 2021 /pmc/articles/PMC8437922/ /pubmed/34515837 http://dx.doi.org/10.1007/s00395-021-00893-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Practical Guideline
Lecour, Sandrine
Andreadou, Ioanna
Bøtker, Hans Erik
Davidson, Sean M.
Heusch, Gerd
Ruiz-Meana, Marisol
Schulz, Rainer
Zuurbier, Coert J.
Ferdinandy, Péter
Hausenloy, Derek J.
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
title IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
title_full IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
title_fullStr IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
title_full_unstemmed IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
title_short IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
title_sort improving preclinical assessment of cardioprotective therapies (impact) criteria: guidelines of the eu-cardioprotection cost action
topic Practical Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437922/
https://www.ncbi.nlm.nih.gov/pubmed/34515837
http://dx.doi.org/10.1007/s00395-021-00893-5
work_keys_str_mv AT lecoursandrine improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT andreadouioanna improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT bøtkerhanserik improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT davidsonseanm improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT heuschgerd improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT ruizmeanamarisol improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT schulzrainer improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT zuurbiercoertj improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT ferdinandypeter improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT hausenloyderekj improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction
AT improvingpreclinicalassessmentofcardioprotectivetherapiesimpactcriteriaguidelinesoftheeucardioprotectioncostaction